1-10 of 10
Giovanni Abbadessa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT

MHD Monzr M. Al Malki, Melhem M. Solh, Anurag K. Singh, Rushang D. Patel, Denis-Claude Roy, Agata Drewniak, Gu Mi, Lorraine Tracey, Giovanni Abbadessa, Richard E. Champlin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4921.
https://doi.org/10.1182/blood-2023-173241
Published: 2023
Journal Articles

A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Marina Y. Konopleva, Vijaya Raj Bhatt, Ioannis Mantzaris, Abhishek Maiti, Krishna Gundabolu, Kyle Jensen, Jolie Schafer, Gu Mi, Agata Drewniak, Heidi Krenz, Rao Saleem, Giovanni Abbadessa, Naval Daver
Journal: Blood
Blood (2023) 142 (Supplement 1): 5972.
https://doi.org/10.1182/blood-2023-174030
Published: 2023
Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Ashish Bajel, Sylvain Garciaz, Pinkal Desai, Gerwin A Huls, Abhishek Maiti, Mojca Jongen-Lavrencic, Nicolas Boissel, Stephane De Botton, David C. de Leeuw, Shaun Fleming, C. Michel Zwaan, Martha Arellano, David Avigan, Jennifer N. Saultz, Ioannis Mantzaris, Kyle Jensen, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Anthony Selwyn Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 3474.
https://doi.org/10.1182/blood-2023-173162
Published: 2023
Journal Articles

Significant Cytokine Release Syndrome Risk Model with T-Cell Engaging Therapies

Penelope Lafeuille, William Blumentals, Claire Brulle Wohlhueter, Weixi Chen, Chao Sang, Sydney Manning, Silvy Saltzman, Jan Canvin, Susan Richard, Cris Kamperschroer, Giovanni Abbadessa, Aniketh Talwai, Caroline Der-Nigoghossian, Yahav Itzkovich, Vibhu Agarwal, Rahul Jain, Tanmay Jain, Jacob Aptekar, Stephan Grupp
Journal: Blood
Blood (2023) 142 (Supplement 1): 3629.
https://doi.org/10.1182/blood-2023-181985
Published: 2023
Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei
Journal: Blood
Blood (2022) 140 (Supplement 1): 7476–7477.
https://doi.org/10.1182/blood-2022-166000
Published: 2022
Journal Articles

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Carmelo Carlo-Stella, Pier Luigi Luigi Zinzani, Anna Sureda, Luís Francisco Araújo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh, Krimo Bouabdallah, Guillaume Cartron, Won Seog Kim, Raul Cordoba, Youngil Koh, Alessandro Re, Daniela Alves, Martine E.D Chamuleau, Steven Le Gouill, Armando Lopez-Guillermo, Maria Ilidia Moreira, Marjolein W.M. Van Der Poel, Giovanni Abbadessa, Robin Meng, Ran Ji, Lucie Lepine, Rao Saleem, Vincent Ribrag
Journal: Blood
Blood (2021) 138 (Supplement 1): 4362.
https://doi.org/10.1182/blood-2021-148431
Published: 2021
Journal Articles

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

Andre Baruchel, Jonas Abrahamsson, Yves Bertrand, Oscar Gonzalez, Karsten Nysom, Willy Quinones, Carmelo Rizzari, Jochen Buechner, Simone Cesaro, Joaquin Duarte, Franca Fagioli, Hyoung Jin Kang, Antonis Kattamis, Guy Leverger, Kathleen Ludwig, Monica L Makiya, Concetta Micalizzi, Brigitte Nelken, Camilla Tøndel, Keon Hee Yoo, Inna Ivanina, Claire Brillac, Lynn Wang, Corina Oprea, Giovanni Abbadessa, C. Michel Zwaan
Journal: Blood
Blood (2021) 138 (Supplement 1): 516.
https://doi.org/10.1182/blood-2021-150272
Published: 2021
Journal Articles

Specific Inhibition of AKT with ARQ 092, an Orally-Available Selective AKT Inhibitor, Attenuates Acute Vaso-Occlusive Events in Sickle Cell Disease

Jing Li, PhD, Kyungho Kim, PhD, Alan Tseng, Andrew Barazia, PhD, Seock-Won Youn, Giovanni Abbadessa, MD, Yi Yu, PhD, Brian Schwartz, MD, Robert K Andrews, PhD, Victor R. Gordeuk, MD, Jaehyung Cho, PhD
Journal: Blood
Blood (2016) 128 (22): 160.
https://doi.org/10.1182/blood.V128.22.160.160
Published: 2016
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Sean D. Reiff, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Virginia M. Goettl, DVM , PhD, Amy J. Johnson, PhD, Sudharsan Eathiraj, Giovanni Abbadessa, MD, Brian Schwartz, MD, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2016) 128 (22): 3232.
https://doi.org/10.1182/blood.V128.22.3232.3232
Published: 2016
Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD
Journal: Blood
Blood (2015) 126 (23): 5116.
https://doi.org/10.1182/blood.V126.23.5116.5116
Published: 2015